This study estimates changes in reimbursements for orally administered anticancer drugs paid by commercial health plans from 2000 through 2014.

Prescription drug pricing and changes in prices for existing drugs have been under intense scrutiny recently. For anticancer medications, high drug prices have the potential to affect access and adherence to therapies and increase financial burden for patients. Given the rapidly evolving drug pricing landscape, it is important to evaluate recent pricing for anticancer medications. This study’s objectives were to estimate changes in reimbursements for orally administered anticancer drugs paid by commercial health plans from 2000 through 2014, focusing on reimbursements during the year of product launch and changes in reimbursements over time.

Source: http://oncology.jamanetwork.com/article.aspx?articleid=2517398